Evaluation of biomarker modulation by fenretinide in prostate cancer patients

European Urology

Volumn 35, Issue 5-6, 1999, Pages 429-438

  Urban, D ^a   Myers, R ^a   Manne, U ^a   Weiss, H ^a   Mohler, J ^a   Perkins, D ^a   Markiewicz, M ^a   Lieberman, R ^a   Kelloff, G ^a   Marshall, M ^a   Grizzle, W ^a  

^a Alabama   (United States)

Author keywords

(4 Hydroxyphenyl)retinamide; Chemoprevention; Fenretinide; Prostate cancer; Surrogate endpoint biomarker

Indexed keywords

BIOLOGICAL MARKER; CANCER GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FENRETINIDE; GLYCOPROTEIN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; BIOPSY; CELL STRUCTURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; HEADACHE; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PLOIDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; XEROSTOMIA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; FENRETINIDE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0032917375     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000019875     Document Type: Conference Paper

References (52)